Explore our strategy and projects
to learn about the future of our company
Results FY 2024 (€/MLN)
1,185
Revenues
394
Adjusted EBITDA
236
Adjusted net profit
241
Free cash flow
Stock price
Discover morePress releases
02/07/25 - 8:10
Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver
07/06/25 - 12:25
Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®

LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.

Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments